StockNews.AI

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

StockNews.AI • 1 minute

JNJNVSABBV
High Materiality8/10

Information

Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: C...

Original source

AI Summary

CMND completed treatment in the second cohort for CMND-100 trial. Positive signals observed in the first cohort regarding safety and efficacy. Cohort results to advance multi-center clinical evaluation for alcohol use disorder. Upcoming data readouts are expected in the coming months. Strong interest in CMND-100 for addressing unmet medical needs.

Sentiment Rationale

Successful trial progression can lead to increased investor confidence and stock price. Historical examples, like other biotech firms that experienced price surges following positive trial outcomes, support this view.

Trading Thesis

The long-term impact is anticipated due to potential commercialization of CMND-100 if trials continue to show promise, resembling patterns seen in successful drug approvals.

Market-Moving

  • CMND completed treatment in the second cohort for CMND-100 trial.
  • Positive signals observed in the first cohort regarding safety and efficacy.
  • Cohort results to advance multi-center clinical evaluation for alcohol use disorder.

Key Facts

  • CMND completed treatment in the second cohort for CMND-100 trial.
  • Positive signals observed in the first cohort regarding safety and efficacy.
  • Cohort results to advance multi-center clinical evaluation for alcohol use disorder.
  • Upcoming data readouts are expected in the coming months.
  • Strong interest in CMND-100 for addressing unmet medical needs.

Companies Mentioned

  • JNJ (JNJ)
  • NVS (NVS)
  • ABBV (ABBV)

Research Analysis

The article signifies a milestone in a crucial clinical trial, likely influencing investor perceptions and future investment.

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Overview of Recent Milestone in Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based clinical-stage biotech company, has announced the successful completion of treatment in all patients of the second cohort of its FDA-approved Phase I/IIa clinical trial. This trial evaluates the effectiveness of CMND-100, an oral drug candidate aimed at addressing Alcohol Use Disorder (AUD). The second cohort, which consisted of six patients, was treated at prestigious clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

Details of the Clinical Trial

The completion of treatment for the second cohort builds on promising outcomes from the first cohort, which noted a favorable safety profile and preliminary efficacy signals such as reduced cravings and withdrawal symptoms. According to Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, “We are pleased to announce the successful completion of treatment in the second cohort, which occurred just a month after receiving DSMB approval to continue enrollment.”

This achievement indicates ongoing progress in the multinational Phase I/IIa study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Topline results from the second cohort are expected in the coming months.

Significance of CMND-100 for Alcohol Use Disorder

Clearmind's dedication to developing CMND-100 reflects a commitment to addressing significant unmet medical needs in the treatment of AUD. As alcohol use disorder presents serious health challenges, the potential of CMND as an innovative therapy is gaining strong interest among clinical researchers and medical communities.

  • The trial includes international participation across multiple leading clinical sites.
  • Results from the initial cohort suggest a promising therapeutic avenue for AUD.
  • Safety and efficacy results from the ongoing trials could reshape treatment protocols for alcohol use disorders.

About Clearmind Medicine Inc.

Clearmind Medicine, listed on Nasdaq under the symbol CMND and on the Frankfurt Stock Exchange under “CWY0”, is a clinical-stage psychedelic pharmaceutical biotech company. The firm specializes in creating novel psychedelic-derived therapeutics to address widespread and underserved health issues, including alcohol use disorder.

The Company's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary. Clearmind is also open to acquiring further intellectual property to enhance its innovative portfolio.

Contact Information

For more information about Clearmind Medicine Inc., visit their website or reach out through:

This article may contain forward-looking statements based on management's current expectations. Actual results may differ materially from those expressed or implied.

Related News